DexCom (DXCM) - FREE Research Report

Gregg Terrance H who is Ceo at DexCom sold 9,000 shares at $27.00 on Sept. 4, 2013. Following this transaction, the Ceo owned 759,889 shares meaning that the stake was reduced by 1.17% with the 9,000 share transaction.

The shares most recently traded at $26.77, down $0.23, or 0.86% since the insider transaction.

The average volume for DexCom has been 577,800 shares per day over the past 30 days. DexCom has a market cap of $1.9 billion and is part of the health care sector and health services industry. Shares are up 96.25% year to date as of the close of trading on Wednesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently there are 7 analysts that rate DexCom a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000